Human Genome (HGSI) Receives U.S. FDA Response Letter for Anthrax Treatment Raxibacumab
Tweet Send to a Friend
Human Genome Sciences, Inc. (NASDAQ: HGSI) today announced that it has received a Complete Response Letter from the U.S. Food ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
